The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | ASH 2017: CLL combination therapy highlights
Now that hematological oncologists have an arsenal of novel single agents, the natural next step is to determine the best combinations of these agetns, both with one another and with standard chemotherapeutics. In this interview, Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discusses advancements in chronic lymphocytic leukemia (CLL) therapy, particularly novel combinations, which have shown clinical promise. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,
